Drug Type Small molecule drug |
Synonyms Alethine beta, Beta LT, Beta alethine + [3] |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC10H22N4O2S2 |
InChIKeyWELIVEBWRWAGOM-UHFFFAOYSA-N |
CAS Registry646-08-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Phase 2 | US | - | 22 Mar 2021 |
B-Cell Lymphoma | Phase 2 | US | 01 Aug 2000 | |
Low Grade B-Cell Non-Hodgkin's Lymphoma | Phase 2 | US | 01 Aug 2000 | |
Multiple Myeloma | Phase 2 | US | 01 Aug 2000 | |
Plasmacytoma | Phase 2 | US | 01 Aug 2000 | |
Precancerous Conditions | Phase 2 | US | 01 Aug 2000 | |
Non-Hodgkin Lymphoma | Phase 2 | CA | - | |
Non-Hodgkin Lymphoma | Phase 2 | US | - | |
Waldenstrom Macroglobulinemia | Phase 2 | - | - |